CN106061966B - 用作溴区结构域抑制剂的双环杂环衍生物 - Google Patents
用作溴区结构域抑制剂的双环杂环衍生物 Download PDFInfo
- Publication number
- CN106061966B CN106061966B CN201580004048.2A CN201580004048A CN106061966B CN 106061966 B CN106061966 B CN 106061966B CN 201580004048 A CN201580004048 A CN 201580004048A CN 106061966 B CN106061966 B CN 106061966B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- synthesis
- pharmaceutically acceptable
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1=*[U]C(C)=C1C* Chemical compound CC1=*[U]C(C)=C1C* 0.000 description 25
- ULQPYWYADORUAC-UHFFFAOYSA-N CC(C)(CC(N(C)c1c2)O)c1cc(C)c2OC Chemical compound CC(C)(CC(N(C)c1c2)O)c1cc(C)c2OC ULQPYWYADORUAC-UHFFFAOYSA-N 0.000 description 1
- YRGMYORZKFPBOU-UHFFFAOYSA-N CC(C)(Cc(c(N1)c2)ccc2OC)C1=O Chemical compound CC(C)(Cc(c(N1)c2)ccc2OC)C1=O YRGMYORZKFPBOU-UHFFFAOYSA-N 0.000 description 1
- XPCSTLGFZSTVNZ-UHFFFAOYSA-N CC(N1C)=CNC1=O Chemical compound CC(N1C)=CNC1=O XPCSTLGFZSTVNZ-UHFFFAOYSA-N 0.000 description 1
- NDMTYHHSZSTZLJ-UHFFFAOYSA-N CC(c1ccncc1)OS(C)(=O)=O Chemical compound CC(c1ccncc1)OS(C)(=O)=O NDMTYHHSZSTZLJ-UHFFFAOYSA-N 0.000 description 1
- IHUITJCCHPJIPP-UHFFFAOYSA-N CCC(N1CCC(CNc(c(N)c2)cc(C3C(C)CC3)c2-c2c(C)[o]nc2C)CC1)=[U-] Chemical compound CCC(N1CCC(CNc(c(N)c2)cc(C3C(C)CC3)c2-c2c(C)[o]nc2C)CC1)=[U-] IHUITJCCHPJIPP-UHFFFAOYSA-N 0.000 description 1
- GSECEYIGIYZLKK-UHFFFAOYSA-N CCOC(CNc(c([NH+]([O-])I)c1)cc(-c2c(C)[o]nc2C)c1OC)=O Chemical compound CCOC(CNc(c([NH+]([O-])I)c1)cc(-c2c(C)[o]nc2C)c1OC)=O GSECEYIGIYZLKK-UHFFFAOYSA-N 0.000 description 1
- ZMYZMWGHDSZNAZ-UHFFFAOYSA-N Cc([nH]nc1C)c1-c(cc(c(N1)c2)NCC1=O)c2O Chemical compound Cc([nH]nc1C)c1-c(cc(c(N1)c2)NCC1=O)c2O ZMYZMWGHDSZNAZ-UHFFFAOYSA-N 0.000 description 1
- XYYXDARQOHWBPO-UHFFFAOYSA-N Cc1nnc(C)[nH]1 Chemical compound Cc1nnc(C)[nH]1 XYYXDARQOHWBPO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN125/CHE/2014 | 2014-01-09 | ||
| IN125CH2014 | 2014-01-09 | ||
| PCT/IB2015/050090 WO2015104653A1 (en) | 2014-01-09 | 2015-01-06 | Bicyclic heterocyclic derivatives as bromodomain inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106061966A CN106061966A (zh) | 2016-10-26 |
| CN106061966B true CN106061966B (zh) | 2018-12-07 |
Family
ID=52462967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580004048.2A Expired - Fee Related CN106061966B (zh) | 2014-01-09 | 2015-01-06 | 用作溴区结构域抑制剂的双环杂环衍生物 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10077259B2 (https=) |
| EP (1) | EP3092227B1 (https=) |
| JP (1) | JP6480944B2 (https=) |
| KR (1) | KR102394518B1 (https=) |
| CN (1) | CN106061966B (https=) |
| AU (1) | AU2015205339B2 (https=) |
| BR (1) | BR112016015311B1 (https=) |
| CA (1) | CA2934788C (https=) |
| CL (1) | CL2016001737A1 (https=) |
| CY (1) | CY1122046T1 (https=) |
| DK (1) | DK3092227T3 (https=) |
| EA (1) | EA029224B1 (https=) |
| ES (1) | ES2687497T3 (https=) |
| HR (1) | HRP20181650T1 (https=) |
| HU (1) | HUE041546T2 (https=) |
| IL (1) | IL246140B (https=) |
| LT (1) | LT3092227T (https=) |
| MA (1) | MA39172B1 (https=) |
| MX (1) | MX2016009052A (https=) |
| MY (1) | MY190835A (https=) |
| PE (1) | PE20161021A1 (https=) |
| PH (1) | PH12016501355B1 (https=) |
| PL (1) | PL3092227T3 (https=) |
| PT (1) | PT3092227T (https=) |
| RS (1) | RS57586B1 (https=) |
| SA (1) | SA516371448B1 (https=) |
| SG (1) | SG11201604916YA (https=) |
| SI (1) | SI3092227T1 (https=) |
| UA (1) | UA117165C2 (https=) |
| WO (1) | WO2015104653A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| JP2018522871A (ja) * | 2015-07-02 | 2018-08-16 | オリオン コーポレーション | ブロモドメイン阻害剤としての二環式複素環誘導体 |
| JP2018527340A (ja) | 2015-08-11 | 2018-09-20 | ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ | アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用 |
| WO2017024406A1 (en) | 2015-08-11 | 2017-02-16 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| KR102784592B1 (ko) | 2015-08-12 | 2025-03-19 | 에피제네틱스, 인크. | 치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도 |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CN105198871A (zh) * | 2015-11-06 | 2015-12-30 | 中国药科大学 | 一类喹喔啉酮类化合物及其制备方法和用途 |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| EP3445750A4 (en) * | 2016-04-18 | 2019-11-27 | Celgene Quanticel Research, Inc. | THERAPEUTIC COMPOUNDS |
| DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| EP3558976A1 (de) | 2016-12-22 | 2019-10-30 | Bayer CropScience Aktiengesellschaft | Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| CN110337436A (zh) | 2016-12-22 | 2019-10-15 | 拜耳作物科学股份公司 | 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途 |
| CN108570038B (zh) * | 2017-03-08 | 2021-09-28 | 中国科学院上海药物研究所 | 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途 |
| WO2018195155A1 (en) | 2017-04-18 | 2018-10-25 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| CN110092782B (zh) * | 2018-01-30 | 2022-10-21 | 中国科学院广州生物医药与健康研究院 | 一种苯并六元氮杂环化合物及其制备方法和应用 |
| CN110960528A (zh) * | 2018-09-30 | 2020-04-07 | 四川大学 | Ar和bet双重抑制剂及其用途 |
| US11192900B2 (en) | 2018-10-30 | 2021-12-07 | Nuvation Bio Inc. | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors |
| CA3132934A1 (en) | 2019-04-11 | 2020-10-15 | Eila Luukkonen | Crystalline form of a bet-inhibitor and manufacture thereof |
| KR102677015B1 (ko) | 2019-07-02 | 2024-06-19 | 누베이션 바이오 인크. | Bet 억제제로서의 헤테로시클릭 화합물 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| KR102600176B1 (ko) * | 2021-10-18 | 2023-11-10 | 주식회사 사피엔스바이오 | 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| AU2024335572A1 (en) * | 2023-09-07 | 2026-03-19 | Xenon Pharmaceuticals Inc. | Benzo-fused heterocyclic compounds and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013027168A1 (en) * | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10259176A (ja) * | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
| AU2005288080B2 (en) * | 2004-09-28 | 2011-10-13 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compound |
| MY144974A (en) * | 2005-06-14 | 2011-11-30 | Eisai R&D Man Co Ltd | 1,2-di(cyclic) substituted benzene derivatives |
| JP5191155B2 (ja) * | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| TW200918058A (en) * | 2007-08-31 | 2009-05-01 | Organon Nv | TSH receptor antagonizing tetrahydroquinoline compounds |
| JP5438008B2 (ja) * | 2007-09-21 | 2014-03-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ＭＤＭ２とｐ５３の間の相互作用の阻害剤 |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| WO2010074807A1 (en) * | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2012064744A2 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
| GB201106750D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) * | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| EP2844247A4 (en) * | 2012-04-20 | 2015-11-25 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
| EP2844260A4 (en) * | 2012-04-30 | 2016-06-29 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
| EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| JP6453845B2 (ja) * | 2013-03-27 | 2019-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｒｄ４阻害薬としてのジヒドロキナゾリノン類似体 |
-
2015
- 2015-01-06 HU HUE15703314A patent/HUE041546T2/hu unknown
- 2015-01-06 ES ES15703314.3T patent/ES2687497T3/es active Active
- 2015-01-06 SI SI201530357T patent/SI3092227T1/sl unknown
- 2015-01-06 MX MX2016009052A patent/MX2016009052A/es unknown
- 2015-01-06 UA UAA201608674A patent/UA117165C2/uk unknown
- 2015-01-06 US US15/110,361 patent/US10077259B2/en active Active
- 2015-01-06 JP JP2016545312A patent/JP6480944B2/ja not_active Expired - Fee Related
- 2015-01-06 EP EP15703314.3A patent/EP3092227B1/en active Active
- 2015-01-06 BR BR112016015311-1A patent/BR112016015311B1/pt not_active IP Right Cessation
- 2015-01-06 PE PE2016001002A patent/PE20161021A1/es active IP Right Grant
- 2015-01-06 MY MYPI2016001265A patent/MY190835A/en unknown
- 2015-01-06 AU AU2015205339A patent/AU2015205339B2/en not_active Ceased
- 2015-01-06 EA EA201691404A patent/EA029224B1/ru not_active IP Right Cessation
- 2015-01-06 CN CN201580004048.2A patent/CN106061966B/zh not_active Expired - Fee Related
- 2015-01-06 HR HRP20181650TT patent/HRP20181650T1/hr unknown
- 2015-01-06 WO PCT/IB2015/050090 patent/WO2015104653A1/en not_active Ceased
- 2015-01-06 DK DK15703314.3T patent/DK3092227T3/en active
- 2015-01-06 LT LTEP15703314.3T patent/LT3092227T/lt unknown
- 2015-01-06 PT PT15703314T patent/PT3092227T/pt unknown
- 2015-01-06 CA CA2934788A patent/CA2934788C/en active Active
- 2015-01-06 PL PL15703314T patent/PL3092227T3/pl unknown
- 2015-01-06 KR KR1020167021643A patent/KR102394518B1/ko not_active Expired - Fee Related
- 2015-01-06 MA MA39172A patent/MA39172B1/fr unknown
- 2015-01-06 RS RS20180847A patent/RS57586B1/sr unknown
- 2015-01-06 SG SG11201604916YA patent/SG11201604916YA/en unknown
-
2016
- 2016-06-09 IL IL246140A patent/IL246140B/en active IP Right Grant
- 2016-07-03 SA SA516371448A patent/SA516371448B1/ar unknown
- 2016-07-07 CL CL2016001737A patent/CL2016001737A1/es unknown
- 2016-07-08 PH PH12016501355A patent/PH12016501355B1/en unknown
-
2018
- 2018-08-01 US US16/051,913 patent/US10590118B2/en active Active
- 2018-09-18 CY CY20181100961T patent/CY1122046T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013027168A1 (en) * | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106061966B (zh) | 用作溴区结构域抑制剂的双环杂环衍生物 | |
| KR100908155B1 (ko) | 히스타민 ｈ3 수용체 리간드로서 유용한테트라하이드로나프티리딘 유도체 | |
| AU2014262622A1 (en) | Benzimidazole derivatives as bromodomain inhibitors | |
| WO2014128655A1 (en) | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors | |
| CN107709298A (zh) | 作为溴结构域抑制剂的螺[环丁烷‑1,3’‑二氢吲哚]‑2’‑酮衍生物 | |
| WO2002032872A1 (fr) | Composes a noyau aromatique azote | |
| CN104736533B (zh) | Vegfr3抑制剂 | |
| TW201609707A (zh) | 新穎之經取代嘧啶化合物 | |
| WO2019242689A1 (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
| CN107810185A (zh) | 作为溴结构域抑制剂的二环杂环衍生物 | |
| HK1230600A1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| HK1230600B (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| NZ721993B2 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| HK1259107A1 (zh) | 氨基唑衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181207 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |